768 related articles for article (PubMed ID: 33177178)
1. Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion.
Ham S; Yun SP; Kim H; Kim D; Seo BA; Kim H; Shin JY; Dar MA; Lee GH; Lee YI; Kim D; Kim S; Kweon HS; Shin JH; Ko HS; Lee Y
Sci Transl Med; 2020 Nov; 12(569):. PubMed ID: 33177178
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of AIMP2 aggregation attenuates α-synuclein aggregation and toxicity in Parkinson's disease.
Shin JY; Lee B; Ham S; Kim JH; Kim H; Kim H; Jo MG; Kim HJ; Park SW; Kweon HS; Kim YJ; Yun SP; Lee Y
Biomed Pharmacother; 2022 Dec; 156():113908. PubMed ID: 36283223
[TBL] [Abstract][Full Text] [Related]
3. Lewy body-associated proteins: victims, instigators, or innocent bystanders? The case of AIMP2 and alpha-synuclein.
Lashuel HA; Novello S
Neurobiol Dis; 2021 Aug; 156():105417. PubMed ID: 34102275
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
5. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
6. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
[TBL] [Abstract][Full Text] [Related]
7. Prolyl-isomerase Pin1 accumulates in lewy bodies of parkinson disease and facilitates formation of alpha-synuclein inclusions.
Ryo A; Togo T; Nakai T; Hirai A; Nishi M; Yamaguchi A; Suzuki K; Hirayasu Y; Kobayashi H; Perrem K; Liou YC; Aoki I
J Biol Chem; 2006 Feb; 281(7):4117-25. PubMed ID: 16365047
[TBL] [Abstract][Full Text] [Related]
8. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
[TBL] [Abstract][Full Text] [Related]
9. Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils.
Zhang B; Kehm V; Gathagan R; Leight SN; Trojanowski JQ; Lee VM; Luk KC
Methods Mol Biol; 2019; 1948():45-57. PubMed ID: 30771169
[TBL] [Abstract][Full Text] [Related]
10. Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism.
Osterberg VR; Spinelli KJ; Weston LJ; Luk KC; Woltjer RL; Unni VK
Cell Rep; 2015 Mar; 10(8):1252-60. PubMed ID: 25732816
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease.
Liani E; Eyal A; Avraham E; Shemer R; Szargel R; Berg D; Bornemann A; Riess O; Ross CA; Rott R; Engelender S
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5500-5. PubMed ID: 15064394
[TBL] [Abstract][Full Text] [Related]
12. α-Synuclein binds and sequesters PIKE-L into Lewy bodies, triggering dopaminergic cell death via AMPK hyperactivation.
Kang SS; Zhang Z; Liu X; Manfredsson FP; He L; Iuvone PM; Cao X; Sun YE; Jin L; Ye K
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1183-1188. PubMed ID: 28096359
[TBL] [Abstract][Full Text] [Related]
13. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
14. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
[TBL] [Abstract][Full Text] [Related]
15. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
Bickle L; Hopwood JJ; Karageorgos L
Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442
[TBL] [Abstract][Full Text] [Related]
16. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
17. Synphilin isoforms and the search for a cellular model of lewy body formation in Parkinson's disease.
Eyal A; Engelender S
Cell Cycle; 2006 Sep; 5(18):2082-6. PubMed ID: 16969096
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease.
Engelender S
Autophagy; 2008 Apr; 4(3):372-4. PubMed ID: 18216494
[TBL] [Abstract][Full Text] [Related]
19. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
20. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
von Coelln R; Thomas B; Andrabi SA; Lim KL; Savitt JM; Saffary R; Stirling W; Bruno K; Hess EJ; Lee MK; Dawson VL; Dawson TM
J Neurosci; 2006 Apr; 26(14):3685-96. PubMed ID: 16597723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
